A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
Completed · Phase 2
Conditions studied: Squamous Cell Carcinoma of Anal Canal
In brief
The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy.
Key facts
- Study ID
- NCT03597295
- Run by
- Incyte Corporation
- People needed
- 94
- Starts
- 2018-10-08
- Expected to finish
- 2021-11-10
- Last updated by the study team
- 2025-08-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Ability to comprehend and willingness to sign a written informed consent form.
- Confirmed diagnosis of locally advanced or metastatic SCAC.
- Must have received (or been intolerant to or ineligible for) at least 1 prior line of platinum-based chemotherapy and received no more than 2 prior systemic treatments.
- Must have measurable disease by RECIST v1.1.
- Eastern Cooperative Oncology Group performance status of 0 to 1.
- If HIV-positive, then all of the following criteria must also be met: CD4+ count ≥ 300/μL, undetectable viral load, and receiving highly active antiretroviral therapy.
You may not qualify if…
- Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug; 6 weeks for mitomycin C.
- Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy, 6 months for thoracic region radiotherapy that is > 30 Gy.
- Prior treatment with programmed cell death protein 1 (PD-1) or programmed cell death ligand protein 1 (PD-L1)-directed therapy.
- Active autoimmune disease requiring systemic immunosuppression.
- Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Known active hepatitis infection.
- Active infections requiring systemic therapy.
- Is pregnant or breastfeeding or is expecting to conceive or father children within the projected duration of the study, from screening through 6 months after the last dose of study drug.
Where it is running
- City of Hope National Medical Center — Duarte, California, United States
- UC Davis Comprehensive Cancer Center — Sacramento, California, United States
- Ridley-Tree Cancer Center — Santa Barbara, California, United States
- Maryland Oncology Hematology P.A. — Rockville, Maryland, United States
- Texas Oncology-Baylor Charles A. Sammons — Dallas, Texas, United States
- Texas Oncology-McKinney — McKinney, Texas, United States
- Renovatio Clinical — Spring, Texas, United States
- Zna Middelheim — Antwerp, Belgium
- Hopital Erasme — Brussels, Belgium
- Aarhus Universitets Hospital — Aarhus, Denmark
- Herlev Og Gentofte Hospital — Herlev, Denmark
- Vejle Hospital — Vejle, Denmark
- Centre Hospitalier Universitaire de Besancon — Besançon, France
- CHU Hopital De La Timone — Marseille, France
- Icm Montpellier — Montpellier, France
- Hopital Universitaire Pitie-Salpetriere — Paris, France
- Chu de Rennes - Hôpital Pontchaillou — Rennes, France
- Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau — Saint-Herblain, France
- CHU Toulouse Hopital Rangueil — Toulouse, France
- University Medical Centre Hamburg-Eppendorf, Centre of Oncology — Hamburg, Germany
- Asklepios Klinik Altona — Hamburg, Germany
- Azienda Ospedaliero Universitaria Ospedali Riuniti — Ancona, Italy
- Ospedale A. Perrino - Brindisi — Brindisi, Italy
- A.O.U. Policlinico V. Emanuele G. Rodolico — Catania, Italy
- Ospedale Degli Infermi - Faenza — Faenza, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.